ANNUAL REPORT

LIFEHOUSE GYNAECOLOGICAL ONCOLOGY GROUP

2017

Prepared by
Professor Jonathan Carter

MBBS, DipRACOG, FACS, FRANZCOG, MS, MD, CGO
Professor Gynaecological Oncology, The University of Sydney
Head, Lifehouse Gynaecological Oncology Group

Providing Excellence in
Teaching, Research, Education, Patient Care, Administration
# Table of Contents

Introduction .................................................................................................................. 4

Highlights ...................................................................................................................... 5

Summary Statistics ......................................................................................................... 6
  New Cancers .................................................................................................................. 6
  In Patient ...................................................................................................................... 6
  Out Patient ................................................................................................................... 6
  Major Surgery .............................................................................................................. 7
  Minor Surgery ............................................................................................................. 7
  LOS ................................................................................................................................. 7
  KPI’s ............................................................................................................................... 7
  AE’s Grade 3 & 4 .......................................................................................................... 7
  Meeting Attendance .................................................................................................... 8

Publications ................................................................................................................... 9

Submitted manuscripts ................................................................................................ 10

Book Chapters .............................................................................................................. 10

National Presentations .................................................................................................. 10

State Presentations ....................................................................................................... 12

Local and Regional Presentations ................................................................................ 12

Administrative Responsibilities & Committees ........................................................... 13

PhD & Research Supervision ...................................................................................... 14

Grant, Trial & Manuscript Reviews .............................................................................. 15

RANZCOG Activities .................................................................................................... 16

Ethics Submissions ....................................................................................................... 16

Grants Submissions ...................................................................................................... 17

Memberships in Professional Organizations ................................................................. 17

Course Organization or Instruction ............................................................................. 18

Invited Lectureship, Guest, Program Chair, Grand Rounds Presentations .................. 19

Teaching, Medical Student & University Activities ...................................................... 19

Courses & Conferences Attended ................................................................................ 21

Fundraising, Media ....................................................................................................... 23

Research ......................................................................................................................... 24
**Introduction**

It is an honor and privilege, as Head of the Lifehouse Gynaecologic Oncology Group, to present the 2017 Annual Report for the Lifehouse Gynaecologic Oncology Group.

This year concludes our 4\textsuperscript{th} year within Lifehouse. My Department continues to develop and expand. Our senior medical staff comprise myself, A/Prof Selvan Pather, A/Prof Sam Saidi, A/Prof Trevor Tejada-Berges and Dr Marcelo Nascimento. Our senior nurses are Shannon Philp, our Nurse Practitioner and Belinda Zielony our Clinical Nurse Consultant. Dr King Man Wan and Dr Michael Burling are our Fellows and Dr. Emma Allanson our Lifehouse Gynaecologic Oncology Registrar. Stephen Cotterell remains our data manager and programmer for our Database and Patient Management System. Our ever faithful and reliable Christine Young and Maria Santo are our Patient Navigators.
Highlights

1. Dr Wan presented at ASGO ASM on the use of the modified Caprini Score in gynaecological oncology patients which is an assessment score for venous thrombo-embolism. He was awarded the Tony McCartney Prize for Surgical Innovation.
2. Dr Pearl Tong presented at ASGO ASM on the demographics and outcomes of women with Stage II endometrial carcinoma diagnosed in Australia (2005-2007) using the ANECS data base. She was awarded the Keith Free Fellows Award.
4. Dr Marcelo Nascimento was co-appointed to our Group and the RPAH Peritonectomy Unit.
5. Prof Selvan Pather was appointed to the RPAH Peritonectomy Unit.
6. Prof Saidi performed the first 100 outpatient hysteroscopies in the Lifehouse rapid access hysteroscopy service.
7. Prof Saidi is due to complete the first randomized gynaecological surgical trial at Lifehouse on preoperative carbohydrate loading.
8. Prof Saidi became accredited for Robotic surgery at Chris O'Brien Lifehouse.
9. Prof Pather was a member of the Human research and ethics committee, Sydney Local Health District
10. Prof Pather was an executive member of the Australian Society of Colposcopy and Cervical Pathology (ASCCP)
11. Prof Pather was an examiner of for the CGO subspecialty examination for the RANZCOG
12. Prof Tejada-Berges passed written CGO examination and received full ASGO certification
13. Prof Tejada-Berges performed the 200th robotic surgery at Chris O'Brien Lifehouse
14. Prof Tejada-Berges was interviewed for ABC 7.30 Report on his patient Jo Wallace, and how her son Charlie would cope with her diagnosis.
## Summary Statistics

### Overall Activity

<table>
<thead>
<tr>
<th>Year</th>
<th>Inpatients</th>
<th>Outpatients</th>
<th>New Cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>669</td>
<td>6162</td>
<td>236</td>
</tr>
<tr>
<td>2015</td>
<td>749</td>
<td>6186</td>
<td>230</td>
</tr>
<tr>
<td>2016</td>
<td>827</td>
<td>7194</td>
<td>265</td>
</tr>
<tr>
<td>2017</td>
<td>878</td>
<td>7384</td>
<td>246</td>
</tr>
</tbody>
</table>

### New Cancers Diagnoses

<table>
<thead>
<tr>
<th>Year</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Nascimento</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>51</td>
<td>71</td>
<td>46</td>
<td>62</td>
<td>6</td>
<td></td>
<td>236</td>
</tr>
<tr>
<td>2015</td>
<td>49</td>
<td>66</td>
<td>61</td>
<td>48</td>
<td>6</td>
<td></td>
<td>230</td>
</tr>
<tr>
<td>2016</td>
<td>61</td>
<td>68</td>
<td>59</td>
<td>64</td>
<td>13</td>
<td></td>
<td>265</td>
</tr>
<tr>
<td>2017</td>
<td>31</td>
<td>55</td>
<td>64</td>
<td>55</td>
<td>31</td>
<td>10</td>
<td>246</td>
</tr>
</tbody>
</table>

### New Cancer Diagnosis (Break down by tumour site)

<table>
<thead>
<tr>
<th>Year</th>
<th>New Cancers</th>
<th>Cervix</th>
<th>Corpus</th>
<th>Uterine Sarcoma</th>
<th>Ovary</th>
<th>Sex Cord Stromal</th>
<th>Germ Cell</th>
<th>Vulva</th>
<th>Vagina</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>236</td>
<td>40 (17%)</td>
<td>69 (29%)</td>
<td>11 (4.7%)</td>
<td>55 (23%)</td>
<td>3 (1.3%)</td>
<td>2 (0.85%)</td>
<td>14 (5.9%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>2015</td>
<td>230</td>
<td>32 (14%)</td>
<td>63 (27%)</td>
<td>10 (4.3%)</td>
<td>67 (29%)</td>
<td>2 (0.87%)</td>
<td>4 (1.7%)</td>
<td>11 (4.8%)</td>
<td>2 (0.89%)</td>
</tr>
<tr>
<td>2016</td>
<td>265</td>
<td>35 (13%)</td>
<td>96 (36%)</td>
<td>8 (3%)</td>
<td>67 (25%)</td>
<td>4 (1.5%)</td>
<td>3 (1.1%)</td>
<td>16 (6%)</td>
<td>2 (0.75%)</td>
</tr>
<tr>
<td>2017</td>
<td>246</td>
<td>34 (14%)</td>
<td>80 (33%)</td>
<td>9 (3.7%)</td>
<td>56 (23%)</td>
<td>2 (0.81%)</td>
<td>1 (0.41%)</td>
<td>9 (3.7%)</td>
<td>4 (1.6%)</td>
</tr>
</tbody>
</table>

### In Patient

<table>
<thead>
<tr>
<th>Year</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Nascimento</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>205</td>
<td>202</td>
<td>109</td>
<td>153</td>
<td>0</td>
<td></td>
<td>669</td>
</tr>
<tr>
<td>2015</td>
<td>177</td>
<td>226</td>
<td>149</td>
<td>197</td>
<td>0</td>
<td></td>
<td>750</td>
</tr>
<tr>
<td>2016</td>
<td>181</td>
<td>233</td>
<td>192</td>
<td>206</td>
<td>18</td>
<td></td>
<td>830</td>
</tr>
<tr>
<td>2017</td>
<td>152</td>
<td>175</td>
<td>250</td>
<td>193</td>
<td>90</td>
<td>20</td>
<td>880</td>
</tr>
</tbody>
</table>

Includes Consults

### Out Patient

<table>
<thead>
<tr>
<th>Year</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Nascimento</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>1493</td>
<td>1868</td>
<td>1202</td>
<td>1211</td>
<td>388</td>
<td></td>
<td>6162</td>
</tr>
<tr>
<td>2015</td>
<td>1414</td>
<td>1597</td>
<td>1444</td>
<td>1466</td>
<td>265</td>
<td></td>
<td>6186</td>
</tr>
<tr>
<td>2016</td>
<td>1363</td>
<td>1748</td>
<td>1826</td>
<td>1615</td>
<td>642</td>
<td></td>
<td>7194</td>
</tr>
<tr>
<td>2017</td>
<td>1248</td>
<td>1587</td>
<td>1820</td>
<td>1713</td>
<td>514</td>
<td>502</td>
<td>7384</td>
</tr>
<tr>
<td>Major Surgery</td>
<td>Carter</td>
<td>Pather</td>
<td>Saidi</td>
<td>Tejada-Berges</td>
<td>Nascimento</td>
<td>Other</td>
<td>Total</td>
</tr>
<tr>
<td>---------------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
<td>---------------</td>
<td>------------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>2014</td>
<td>60</td>
<td>114</td>
<td>63</td>
<td>114</td>
<td>0</td>
<td></td>
<td>351</td>
</tr>
<tr>
<td>2015</td>
<td>47</td>
<td>95</td>
<td>81</td>
<td>102</td>
<td>1</td>
<td></td>
<td>326</td>
</tr>
<tr>
<td>2016</td>
<td>58</td>
<td>100</td>
<td>81</td>
<td>89</td>
<td>10</td>
<td></td>
<td>338</td>
</tr>
<tr>
<td>2017</td>
<td>40</td>
<td>69</td>
<td>96</td>
<td>89</td>
<td>15</td>
<td></td>
<td>378</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Minor Surgery</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Nascimento</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>118</td>
<td>67</td>
<td>29</td>
<td>27</td>
<td>0</td>
<td></td>
<td>241</td>
</tr>
<tr>
<td>2015</td>
<td>110</td>
<td>95</td>
<td>54</td>
<td>65</td>
<td>0</td>
<td></td>
<td>324</td>
</tr>
<tr>
<td>2016</td>
<td>106</td>
<td>125</td>
<td>93</td>
<td>92</td>
<td>7</td>
<td></td>
<td>423</td>
</tr>
<tr>
<td>2017</td>
<td>100</td>
<td>78</td>
<td>143</td>
<td>86</td>
<td>25</td>
<td></td>
<td>444</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LOS</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Nascimento</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2.84</td>
<td>2.74</td>
<td>2.12</td>
<td>3.66</td>
<td>-</td>
<td></td>
<td>2.85</td>
</tr>
<tr>
<td>2015</td>
<td>2.85</td>
<td>2.78</td>
<td>2.55</td>
<td>2.89</td>
<td>21</td>
<td></td>
<td>2.82</td>
</tr>
<tr>
<td>2016</td>
<td>3.22</td>
<td>2.97</td>
<td>2.2</td>
<td>2.81</td>
<td>5.64</td>
<td></td>
<td>2.9</td>
</tr>
<tr>
<td>2017</td>
<td>3.65</td>
<td>3.86</td>
<td>1.36</td>
<td>2.34</td>
<td>3.71</td>
<td>2.67</td>
<td>2.78</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>KPI's</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Nascimento</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>21</td>
<td>21</td>
<td>18</td>
<td>26</td>
<td>0</td>
<td></td>
<td>86</td>
</tr>
<tr>
<td>2015</td>
<td>14</td>
<td>15</td>
<td>15</td>
<td>19</td>
<td>0</td>
<td></td>
<td>62</td>
</tr>
<tr>
<td>2016</td>
<td>18</td>
<td>26</td>
<td>19</td>
<td>19</td>
<td>5</td>
<td></td>
<td>87</td>
</tr>
<tr>
<td>2017</td>
<td>10</td>
<td>31</td>
<td>10</td>
<td>10</td>
<td>5</td>
<td>2</td>
<td>68</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AE's Grade 3 &amp; 4</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Nascimento</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>4</td>
<td>5</td>
<td>1</td>
<td>10</td>
<td>0</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>2015</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td></td>
<td>13</td>
</tr>
<tr>
<td>2016</td>
<td>8</td>
<td>15</td>
<td>5</td>
<td>6</td>
<td>0</td>
<td></td>
<td>34</td>
</tr>
<tr>
<td>2017</td>
<td>4</td>
<td>13</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td></td>
<td>22</td>
</tr>
<tr>
<td>Meeting Attendance</td>
<td>Carter</td>
<td>Pather</td>
<td>Saidi</td>
<td>Tejada-Berges</td>
<td>Nascimento</td>
<td>Other</td>
<td>Total</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
<td>---------------</td>
<td>------------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td><strong>2014</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDT</td>
<td>37</td>
<td>34</td>
<td>41</td>
<td>41</td>
<td></td>
<td></td>
<td>41</td>
</tr>
<tr>
<td>M&amp;M</td>
<td>8</td>
<td>6</td>
<td>10</td>
<td>11</td>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td><strong>2015</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDT</td>
<td>41</td>
<td>36</td>
<td>40</td>
<td>37</td>
<td></td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>M&amp;M</td>
<td>8</td>
<td>7</td>
<td>9</td>
<td>9</td>
<td></td>
<td></td>
<td>9</td>
</tr>
<tr>
<td><strong>2016</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDT</td>
<td>35</td>
<td>35</td>
<td>40</td>
<td>39</td>
<td></td>
<td></td>
<td>39</td>
</tr>
<tr>
<td>M&amp;M</td>
<td>9</td>
<td>7</td>
<td>10</td>
<td>11</td>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td><strong>2017</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDT</td>
<td>37</td>
<td>32</td>
<td>42</td>
<td>39</td>
<td>26</td>
<td></td>
<td>64</td>
</tr>
<tr>
<td>M&amp;M</td>
<td>6</td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>4</td>
<td></td>
<td>12</td>
</tr>
</tbody>
</table>
Publications

Carter


Pather


Philp

Submitted manuscripts

Philp


Burling


Book Chapters

Saidi


National Presentations

Carter


Pather

1. Pather S. Management of high grade cervical dysplasia. ASCCP 25th Annual Scientific Meeting. Sofitel Sydney 17 March 2017
6. Pather S. Principles of laser and electrocautery. ASCCP treatment Course, Lifehouse, 12 November 2017
7. Pather S. Laser for treatment of cervical dysplasia. ASCCP treatment Course, Lifehouse, 12 November 2017
8. **Pather S.** Excisional therapy for cervical dysplasia. ASCCP treatment Course, Lifehouse, 12 November 2017

**Tejada-Berges**


**Saidi**


**Other**

2. **Burling M.** ASCO Conference- Change in the pattern of referrals for genetic counselling impact of universal testing for high grade serous carcinoma (HGSC).
State Presentations

Other


Local and Regional Presentations

Carter


Pather

1. **Pather S**. The new cervical screening programme. RPA Reunion week August 2017. RPA Hospital

Saidi


Tejada-Berges

2. **Tejada-Berges T**. Update on NCSP Renewal for GPs. PHN South Western Sydney, NSW. 3rd of May, 2017.

Zielony


**Administrative Responsibilities & Committees**

**Carter**

1. **Carter J.** Lifehouse Medical Advisory Committee (2017).
2. **Carter J.** Lifehouse MDAC Committee (Chairman) (2017).
3. **Carter J.** Lifehouse Theatre Procedure Committee (Chairman) (2017).
6. **Carter J.** SLHD Advanced GI Surgical Program Steering Committee (2017).
7. **Carter J.** MBS Review Committee; Gynaecological Subgroup (2017).
8. **Carter J.** Scientific Advisory Committee (SAC) for Cancer Council NSW’s new research program ‘Pathways to a cancer-free future’ (Pathways) (2017).
10. **Carter J.** Cancer Institute NSW. Ovarian Cancer Clinical Advisory Group. 2017
11. **Carter J.** Family Planning NSW Clinical Advisory Committee. 26th September 2017.

**Pather**

1. **Pather S.** Member of the Ethics committee at the Sydney Local Health District
2. **Pather S.** Member of the Statewide peritonectomy unit.
3. **Pather S.** Member of the Mortality Committee, Chris O’Brien Lifehouse

**Saidi**

1. **Saidi S.** Lead for research, Lifehouse Gynaecological Oncology Group.
2. **Saidi S.** Committee Member NSW Gynaecological Oncology Network Group.
3. **Saidi S.** Research Advisory Committee Member Australian New Zealand Gynaecological Oncology Group (ANZGOG).
4. **Saidi S.** NSW Cervical Screening Program Clinical Advisory Committee Member.
5. **Saidi S.** NSW Ovarian Cancer Clinical Advisory Committee Member.
6. **Saidi S.** Lifehouse Clinical Informatics Committee Member.

**Tejada-Berges**

1. **Tejada-Berges T.** Co-opted Member of Australian Society of Colposcopy and Cervical Pathology (ASCCP) Committee of Management.
2. **Tejada-Berges T.** Educational Committee of International Gynecologic Cancer Society (IGCS).
3. **Tejada-Berges T.** Lifehouse Robotic Steering Committee.
4. **Tejada-Berges T.** Lifehouse Representative to SLHD Surgical Robotics Program Steering Committee.

**Philp**

1. **Philp S.** NSW ACI Gynaecological Oncology Nurses Group (GONG) Executive Committee.
2. **Philp S.** CNSA, Gynaecological Oncology Specialist Practice Network (GYN SPN).
3. **Philp S.** CNSA NP Specialist Practice Network (NP SPN).

**Zielony**

1. **Zielony B.** NSW ACI Gynaecological Oncology Nurses & Allied Health Group (GONG) Executive Committee.
2. **Zielony B.** Cancer Nurses Society of Australia (CNSA) Gynaecological Specialist Practice Network Committee Member.

**PhD & Research Supervision**

**Pather**

1. **Pather S.** Dr Pearl Tong- Stage 2 endometrial cancer and its management.
2. **Pather S.** Dr Unine Herbst – HPV negative high grade cervical dysplasia.
3. **Pather S.** Dr Angela Cong – The role of a virtual reality device in reducing anxiety in patients undergoing colposcopy.
4. **Pather S.** Dr Gaythrie Mayalvaganum – The benefit of concordance meetings in a large dysplasia unit.

**Saidi**

1. **Saidi S.** Eskaroos M. Acceptability of outpatient vs inpatient LEEP biopsy.
2. **Saidi S.** Feddersen J. Bleeding patterns following LEEP biopsy, risk factors and outcomes.
3. **Saidi S.** Grey M. eQOL measurement tool in gynaecological cancer follow-up.
5. **Saidi S.** University of Sydney. Examiner – PhD “Testing the feasibility of a brief nurse-led lifestyle intervention for women with type 1 endometrial cancer”.

**Philp**

1. **Philp S.** Associate Supervisor for Doctor of Philosophy Candidate: Testing the feasibility of a brief nurse-led lifestyle intervention for women with type 1 endometrial cancer, School of Nursing, The University of Sydney. Thesis submitted.
**Grant, Trial & Manuscript Reviews**

**Carter**

2. **Carter J.** Manuscript review ANZJOG-2016-0344. Concordance between initial biopsy and final hysterectomy FIGO grade for endometrioid adenocarcinoma 9th January 2017.

**Pather**

1. **Pather S.** ANZJOG Manuscript No: ANZJOG-2016-0326 Feb 2017

**Saidi**

1. **Saidi S.** IGC-D-17-00286, entitled Setting the threshold for surgical prevention in women at increased risk of ovarian cancer for the International Journal of Gynecological Cancer. 6th November 2017.

**Tejada-Berges**


**Philp**

RANZCOG Activities

Pather

1. **Pather S.** Accredited colposcopy Trainer and evaluator
2. **Pather S.** Examiner for the CGO – Written and OSCE

Saidi


Tejada-Berges

1. **Tejada-Berges T.** RANZCOG NSW/ACT Registrar Education Day. RPAH 26th May 2017. Management of VIN/VAIN. Sydney, NSW.
2. **Tejada-Berges T.** RANZCOG NSW/ACT Registrar Education Day. RPAH 26th May 2017. Sexuality after Cancer Treatment. Sydney, NSW
3. **Tejada-Berges T.** MRANZCOG Written Revision Course: Surgical Pelvic Anatomy, Rydges Hotel, North Sydney, 23rd October 2017.

Other


Ethics Submissions

Pather

1. **Pather S.** Protocol X17 0090 and HREC/17/RPAH/134 A randomized control study to assess the role of a virtual reality device to reduce anxiety in patients undergoing colposcopy at the colposcopy unit. Ethics approval and SSA complete.

Saidi

1. Feddersen J, **Saidi S.** Identifying post-operative bleeding risk factors in patients undergoing LEEP for cervical intraepithelial neoplasia. LH17.048.
4. Allanson E, Saidi S. Tramadol/paracetamol (Zaldiar) compared with oxycodone and paracetamol for the management of post-operative pain. X17-0345 & HREC/17/RPAH/523.

Other

1. Allanson E, Saidi S. Tramadol/paracetamol (Zaldiar) compared with oxycodone and paracetamol for the management of post-operative pain. X17-0345 & HREC/17/RPAH/523.

Grants Submissions

Carter


Pather

1. Pather S. ASCCP – Immunohistochemistry in patients with HPV negative high grade dysplasia. November 2017 $10,000

Memberships in Professional Organizations

Carter

7. Carter J. University of Sydney Association of Professors.

Other

1. Allanson E. RANZCOG.
2. Allanson E. ASGO.
3. Allanson E. ESGO.
4. Allanson E. SGO.
5. Burling M. RANZCOG.
6. Burling M. ASGO.
7. Burling M. ESGO.
8. Wan K. FRANZCOG

Course Organization or Instruction

Carter


Pather

1. Pather S. Course Organiser – ASCCP treatment Course, Chris O Brien Lifehouse 12 November 2017
2. Pather S. Course Organiser- ASCCP 25th Annual Scientific Meeting. Sofitel Sydney 17 March 2017

Tejada-Berges

1. Tejada-Berges T. Member of Organising committee for Australian Society of Colposcopy and Cervical Pathology (ASCCP) Scientific Meeting 2017.

Philp

1. Philp S. Lecturer and Course Coordinator, Cancer and Haematology Nursing, Sydney Nursing School, The University of Sydney.

Zielony


Other

**Invited Lectureship, Guest, Program Chair, Grand Rounds Presentations**

**Carter**

1. **Carter J.** Program/Session Chair. ASGO. Broome Western Australia. 3rd-7th May 2017.

**Pather**

1. **Pather S.** Session Chair, The new cervical screening program for the clinician course. The Hyatt Hotel 11 November 2017.

**Philp**


**Zielony**

1. **Zielony B.** Chair of session, ACI Gynaecological Oncology Nurses & Allied Health Group (GONG) “Endometrial Cancer”, RPAH, 28th April 2017.

**Teaching, Medical Student & University Activities**

**Carter**

1. **Carter J.** SCORPIO. HPV and Vaccination. 13th October 2017.

**Pather**

1. **Pather S.** Medical student lectures on post menopausal bleeding and cervical cancer 04/03/17, 16/05/17, 18/07/17, 08/10/17
2. **Pather S.** Convenor of the 2nd year medical student Scorpio on the management of cervical cancer. 13 October 2017.

**Tejada-Berges**

5. **Tejada-Berges T.** Management of cervical cancer. 16th October 2017

**Saidi**

1. **Saidi S.** Stage 1 PPD (personal portfolio development) interviews. July 2017.
2. **Saidi S.** Stage 2 PPD (personal portfolio development) interviews. August 2017.

**Philp**

1. **Philp S.** Lecturer and Course Coordinator, Cancer and Haematology Nursing, Sydney Nursing School, The University of Sydney.

**Other**

Courses & Conferences Attended

Carter

2. Carter J. Attended ASGO. Broome Western Australia. 3-7th May 2017.

Pather

1. Pather S. ASCCP 25th Annual Scientific Meeting, Sofitel Sydney 17 March 2017
4. Pather S. ASCCP treatment Course, Lifehouse, 12 November 2017

Saidi


Philp


Zielony

5. Zielony B. Chris O'Brien Lifehouse Research Symposium, Chris O'Brien Lifehouse, 10th November 2017

Other

1. Allanson E. APGET 2nd Endoscopy Training Course, Thailand. 3-4th June 2017.
7. **Burling M.** Cancer Australia Update. Sydney. 8th December 2017.
9. **Wan K.** Clinical Immersion. Laparoscopic Hysterectomy. Medtronic and St John of God’s Hospital, Subiaco WA. 5th-7th June 2017.
Fundraising, Media

Tejada-Berges

1. Tejada-Berges T. Interview for ABC report for 7.30 Report
## Research

<table>
<thead>
<tr>
<th>LH Reference</th>
<th>Study Title</th>
<th>Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH13.003</td>
<td>PARAGON (ANZGOG0903) Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms</td>
<td>ANZGOG0903</td>
</tr>
<tr>
<td>LH13.036</td>
<td>A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (OVAR 16)</td>
<td>AGO-OVER 16/VEG11065 5</td>
</tr>
<tr>
<td>LH13.039</td>
<td>Clinical Study No. 1199.15 Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer (OVAR 12)</td>
<td>AGO-OVER 16/VEG11065 5</td>
</tr>
<tr>
<td>LH13.055</td>
<td>IBCSG 24-02/BIG 2-02 : A Phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer (SOFT)</td>
<td>IBCSG 24-02/BIG 2-02</td>
</tr>
<tr>
<td>LH13.056</td>
<td>ANZGOG 0902 : A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (The OUTBACK Trial)</td>
<td>ANZGOG 0902</td>
</tr>
<tr>
<td>LH14.018</td>
<td>An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer - ICON8</td>
<td>Icon8</td>
</tr>
<tr>
<td>LH14.024</td>
<td>AGO-OVAR 2.21 / ENGOT-ov18 : A Prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer (An ENGOT/GCIG Trial ) (OVAR 2.21)</td>
<td>AGO-OVAR 2.21</td>
</tr>
<tr>
<td>LH15.029</td>
<td>EMR 200066_012 : Phase II Randomised Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer</td>
<td>EMR 200066_012</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>LH15.035</td>
<td>Impact of risk-reducing bilateral salpingo-oophorectomy on non-cancer outcomes in young high risk women: A multicentre prospective study (WHAM)</td>
<td>WHAM</td>
</tr>
<tr>
<td>LH15.037</td>
<td>Clinical audit of single surgeon experience with Fast Track Surgery in gynaecological patients</td>
<td>Authorised</td>
</tr>
<tr>
<td>LH15.048</td>
<td>The conservative management of young women, up to age 25, with cervical intraepithelial neoplasia (CIN) 2 (PRINCESS)</td>
<td>PRINCESS</td>
</tr>
<tr>
<td>LH15.049</td>
<td>ANZGOG 1301 : A Phase II Randomised Clinical Trial of Mirena ± Metformin ± Weight Loss Intervention in Patients with Early Stage Cancer of the Endometrium (FEMME)</td>
<td>ANZGOG-1301</td>
</tr>
<tr>
<td>LH16.018</td>
<td>Genomic mechanisms underlying long-term response to treatment in serous ovarian cancer: an Australian Ovarian Cancer Study Project (AOCSS)</td>
<td>Authorised</td>
</tr>
<tr>
<td>LH16.022</td>
<td>Clinical Study No. M13-694 , A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Participants with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</td>
<td>M13-694</td>
</tr>
<tr>
<td>LH16.023</td>
<td>Immunohistochemistry for HPV testing on archived tissue in women with biopsy proven high grade cervical dysplasia and negative HPV testing</td>
<td></td>
</tr>
<tr>
<td>LH16.025</td>
<td>Understanding End of Life Decision Making in Cancer</td>
<td></td>
</tr>
<tr>
<td>LH16.027</td>
<td>Is Preoperative Carbohydrate Loading Tolerable and Beneficial in Gynaecologic Oncology Surgery</td>
<td>CARB LOADING</td>
</tr>
<tr>
<td>LH16.028</td>
<td>The Role of Alpha-Parvin in Human Endometrial Cancer Cells</td>
<td></td>
</tr>
<tr>
<td>LH16.045</td>
<td>INOVATe - Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care</td>
<td></td>
</tr>
<tr>
<td>LH16.047</td>
<td>An audit of the deliverability of Carboplatin and Weekly Paclitaxel as Adjuvant Therapy for Ovarian Fallopian tube and Primary Peritoneal Cancer Patients</td>
<td></td>
</tr>
<tr>
<td>Study ID</td>
<td>Title</td>
<td>Status</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>PHAEDRA</td>
<td>PHAEDRA: A Phase II trial of DuRvalumab (Medi 4736) in Advanced Endometrial Cancer</td>
<td>Recruiting</td>
</tr>
<tr>
<td>LH17.041</td>
<td>Patient satisfaction with LEEP for the treatment of cervical dysplasia</td>
<td>Approved</td>
</tr>
<tr>
<td>LH17.010</td>
<td>Opportunistic salpingectomy at benign surgery prior to the diagnosis of ovarian cancer</td>
<td>Approved</td>
</tr>
<tr>
<td>LH17.032</td>
<td>Patterns of care and variation for women with ovarian cancer in NSW</td>
<td>Approved</td>
</tr>
<tr>
<td>LH17.048</td>
<td>Identifying post-operative bleeding risk factors in patients undergoing LEEP for CIN</td>
<td>Approved</td>
</tr>
</tbody>
</table>